ADA announces Pathway to Stop Diabetes grant recipients
The grants will be awarded over five-to-seven-year terms. Recipients will also receive career support and resources over the grant terms.
The Pathway to Stop Diabetes program is backed by pharmaceutical companies Sanofi, AstraZeneca, Eli Lilly and Company Foundation and Novo Nordisk, among several others.
"Diabetes is a complex, multi-factorial disease that presents significant challenges for discovering methods for prevention, treatment and ultimately cures," Dr. Desmond Schatz, president of medicine and science for the ADA, said. "We need to recruit the best minds to pursue answers to all of the complexities of diabetes and diabetes-related complications so that we can end this devastating disease."
This year's recipients include Dr. Sui Wang, of Harvard Medical School; Dr. Phillip White, of Duke Molecular Physiology Institute at Duke University; Dr. Daniel Ceradini, FACS of the Wyss Department of Plastic Surgery, New York University Langone Medical Center; Dr. Zachary Knight, of the University of California; Dr. Praveen Sethupathy, of the University of North Carolina School of Medicine; and Dr. Andrew Scharenberg, of the Seattle Children's Hospital and Seattle Children's Research Institute.
Schatz is optimistic about the future of the program based on the progress he has witnessed so far.
"Pathway to Stop Diabetes brings novel and exciting approaches to solving challenging areas in our field," Schatz said. "The scientists supported by this program thus far are already making tremendous contributions to the field."
A breakdown of the awards and descriptions of the recipients' projects are available at the ADA home page.